Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
abemaciclib + fulvestrant + trastuzumab
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous, Intramuscular
01
Overview
A combination therapy consisting of abemaciclib (a CDK4/6 inhibitor), fulvestrant (an estrogen receptor antagonist), and trastuzumab (a HER2-targeted monoclonal antibody). This regimen is used primarily for the treatment of hormone receptor (HR)-positive, HER2-positive advanced breast cancer in patients who have received prior treatments. The combination works through multiple mechanisms: abemaciclib inhibits cell cycle progression by targeting CDK4/6, fulvestrant blocks estrogen receptor signaling, and trastuzumab targets HER2 receptors on cancer cells.
- Brand names
- VerzenioHerceptinFaslodex
- Other names
- abemaciclib + trastuzumab + fulvestrant
02
Targets
ESR1 (ERα)CDK4 (Cyclin-dependent kinase 4)ERBB2 (Erb-b2 receptor tyrosine kinase 2)ESR2 (ERβ)CDK6 (Cyclin-dependent kinase 6)
Beyond the preview
Go deeper on abemaciclib + fulvestrant + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on abemaciclib + fulvestrant + trastuzumab.